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Abstract
Immunochromatographic rapid diagnostic tests (RDTs)
have demonstrated significant potential for use as point-of-
care diagnostic tests in resource-limited settings. Most
notably, RDTs for malaria have reached an unparalleled
level of technological maturity and market penetration,
and are now considered an important complement to
standard microscopic methods of malaria diagnosis.
However, the technical development of RDTs for other
infectious diseases, and their uptake within the global
health community as a core diagnostic modality, has been
hindered by a number of extant challenges. These range
from technical and biological issues, such as the need for
better affinity agents and biomarkers of disease, to social,
infrastructural, regulatory and economic barriers, which
have all served to slow their adoption and diminish their
impact. In order for the immunochromatographic RDT
format to be successfully adapted to other disease targets,
to see widespread distribution, and to improve clinical
outcomes for patients on a global scale, these challenges
must be identified and addressed, and the global health
community must be engaged in championing the broader
use of RDTs.
Keywords Rapid diagnostic tests, infectious disease,
immunochromatography, point-of-care, global health
1. Introduction
In 2010, approximately 10 million deaths worldwide were
attributed to bacterial, viral or parasitic infections, and the
vast majority of this mortality occurred in developing
countries. [1] In part, this disproportionately heavy burden
is due to the higher rates of disease incidence observed in
low-income settings, which are causally linked to local
consequences of poverty, such as abundant disease vectors,
poor nutrition, limited access to sanitation and health
education, and environmental determinants like indoor air
pollution. However, the high rates of morbidity and
mortality inflicted by these diseases are due to more
systemic failings — namely, underdeveloped health
infrastructure and severely limited financial resources that
render communities and individuals incapable of bridging
this health care gap.
Surveys conducted by the World Health Organization
(WHO) have found that 72% of the African populace and
42% of the Asian populace is served by minimal or no
infrastructure. [2] Under these conditions, the supply of
electricity and clean water is either unreliable or non-
existent, local medical supplies and laboratory equipment
are limited or totally unavailable, and medical staff are
minimally trained or altogether absent. In many of these
1Nanobiomedicine, 2015, 2:6 | doi: 10.5772/61114
settings, the trappings of a modern and effective health
system — vaccines, chemical prophylactics, therapeutics,
informed medical consultation, and accurate diagnostic
tests — are largely inaccessible luxuries, available only in
distant, centralized clinics.
In such resource-constrained situations, the mere act of
seeking diagnosis for a nascent condition can prove
prohibitively expensive. For instance, in low- and middle-
income countries, the average medical expenses and
income losses faced by tuberculosis (TB) patients over the
course of treatment can amount to more than 50% of their
average annual income, and half of this cost is incurred in
the process of seeking diagnosis. [3] In the absence of local
community clinics, patients are forced to travel to regional
clinics to seek medical consultation, and up until the roll-
out of GeneXpert nucleic acid amplification tests (NAATs)
in 2010, the most sensitive means for diagnosing TB
required 6–8 weeks of cell culture and a follow-up visit. [4]
During this time, patient conditions can worsen, friends
and family can be infected, and presumptive treatment can
be initiated, increasing the risk of spreading drug resist‐
ance. [5]
For vast swathes of the global population, however,
diagnostic consultation never even occurs. In 2012, for
instance, the WHO estimates that 34% of all incident cases
of tuberculosis — 2.9 million new infections — went
undiagnosed, or were not reported to a central authority.
[4] In the same year, approximately 36% of all incident cases
of malaria — 74.5 million new infections — are thought to
have gone undetected. [6] Diagnostic gaps such as these
pose a severe threat to global health, inflicting heavy tolls
of morbidity and mortality upon low-income communities,
wasting valuable medical and financial resources on
inappropriate medicines, and allowing infectious diseases
to continue to proliferate unchecked.
Low-cost diagnostics made available at the point-of-care
(POC) have been heralded as a means of closing these
diagnostic gaps, by providing patients and local health care
practitioners with timely, accurate and actionable diagnos‐
tic data that can inform clinical decisions and ultimately
improve patient outcomes. These broadly distributed
diagnostic resources also play a crucial role in preventing
the further spread of drug resistance, and are critical for
creating the accurate epidemiological models needed to
efficiently direct resource distribution and elimination
campaigns.
Rapid diagnostic tests (RDTs) are leading candidates to fill
this point-of-care diagnostic niche. RDTs are diagnostic
assays which can rapidly indicate the presence of patho‐
gens or pathogen-associated biomarkers in patient sam‐
ples. For the purpose of this review, we will focus on the
most commonly employed form of RDT, immunochroma‐
tographic test strips. These tests, also referred to as “lateral
flow assays,” use membrane-immobilized affinity agents
to screen for the presence of antigens in peripheral patient
fluids. The presence of the targeted antigen in a patient
sample is signalled by the development of a coloured test
line visible to the unaided eye within 5–30 minutes, and this
result is taken to be indicative of infection. Immunochro‐
matographic RDTs typically come in dipstick or cassette
formats, and can be engineered in a multiplexed fashion,
simultaneously testing for the presence of multiple anti‐
gens using a single device.
RDTs are well suited for use in resource-limited settings, in
that they fulfil the ASSURED criteria, potentially demon‐
strating all of the characteristics considered essential for
diagnostics intended for application at the point-of-care. To
varying degrees, RDTs are: 1) Affordable by those at risk of
infection, 2) Sensitive (few false-negatives), 3) Specific,
(few false-positives), 4) User-friendly, (simple to perform
and requiring minimal training), 5) Rapid (to enable
treatment at first visit) and Robust (not requiring refriger‐
ated storage) 6) Equipment-free, and 7) Delivered to those
who need it. [7, 8]
The development of RDTs is ongoing for many infectious
diseases, ranging from HIV and syphilis, to influenza and
tuberculosis, to visceral leishmaniasis and dengue. [9–14]
Malaria RDTs, in particular, have seen significant technical
development and market uptake. Within the field of
malaria diagnostics, there are currently more than 200
commercially available products, [15] and in 2013, 319
million malaria RDTs were sold in 48 different countries.
Of these, 160 million tests were subsidized and distributed
within the public sector by national malaria control
programmes. [16]
However, despite the promise that RDTs have shown for
playing the role of the ideal POC diagnostic test, and
despite the technological maturation seen in RDTs target‐
ing malaria, their broader development and uptake by the
medical community has been limited by a number of
lingering issues. These range from technical and biological
shortcomings - which have served to diminish device
performance and undermine the credibility of RDTs with
patients and health care workers - to social, infrastructural,
regulatory and economic issues, which have slowed their
distribution and adoption at the national and community
levels.
This work will identify these obstacles, explore their
mechanistic roots, and highlight current research and
future actions that may serve to break down barriers to
rapid diagnostic test development and adoption. Through‐
out this discussion, the rise of malaria RDTs will be taken
as an illustrative case study, and the wealth of research into
the subject that has thus far been conducted will be
frequently referenced and used to inform recommenda‐
tions for the advancement of RDTs as a more effective
technological platform.
2. Technical Barriers
In a standard, single-antigen immunochromatographic
RDT, the test strip is composed of several sub-elements
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(Figure 1a), and processing occurs in two steps. First, a pre-
defined volume of the specimen (e.g. whole blood, plasma,
serum, urine, sputum, etc.) is applied to a sample pad,
followed by a washing step in which a buffer formulation
is added either to a separate buffer pad upstream of the
applied specimen, or directly on top of the sample. This
fluid bolus migrates along the length of the test strip, drawn
by capillary forces imposed by the downstream absorption
pad, and first encounters the conjugate pad (Figure 1b). The
conjugate pad contains antibodies that are coupled to
reporter species such as microbeads, dye-cleaving enzymes
or, most commonly, gold nanoparticles. The reporter
antibodies in the conjugate pad are not surface-immobi‐
lized, and thus are free to travel with the fluid front. If
present, antigens in the patient sample form complexes
with these reporter antibodies. These complexes wick
through the nitrocellulose membrane until they contact a
thin band of immobilized capture antibodies, called the test
line. These capture antibodies bind to a unique epitope of
the targeted antigen, and the formation of a full immuno‐
complex (Figure 1c) leads to the concentration of reporter
species, resulting in an optical readout visible to the
unaided eye. Reporter antibodies that are not bound at the
test line continue to wick along the membrane until they
are bound by antibodies immobilized in a downstream
control line (Figure 1c). It is important that the reporter
antibody does not bind to the test line antibody unless the
antigen is present to bridge the two antibodies, and that the
reporter antibody does bind to the antibody used in the
control line. The development of the control line confirms
that the reporter species have mobilized and have main‐
tained binding activity, and that the patient sample has
been drawn across the test line.
Although seemingly simple in theory and design, RDTs are
founded upon several core technologies that are subject to
a number of potential technical vulnerabilities. [17] These
technical complications can render tests either inoperable
or at least unreliable, resulting in diminished test perform‐
ance in the field. Common technical difficulties include
insufficient component stability under thermal stress,
inadequately characterized affinity reagents, the potential
for erroneous readings due to subjective interpretation, the
time-dependence of signal development, insensitivity to
low disease loads, and unsuitability for pathogen quanti‐
tation.
2.1 Susceptibility to Heat and Humidity
One issue common to all RDTs targeting diseases endemic
to tropical or sub-tropical regions is the potential for
degradation due to heat and humidity. Extended exposure
to these conditions can drastically reduce the shelf life of
RDTs, causing warping or degradation of the nitrocellulose
membrane, the hydrolysis of capture antibodies from the
membrane or cleavage of reporter species from the reporter
antibodies, and the irreversible denaturation of the capture
or reporter antibodies. In order to preserve test integrity,
RDT manufacturers recommend continuous product
refrigeration, from the point of manufacture all the way to
rural clinics and the point of use. However, in many
developing countries, cold-chain continuity cannot be
guaranteed, due to both a lack of infrastructure and
variable observance of manufacturer recommendations
along the supply chain.
Figure 1. Standard configuration and mode of action for an immunochromatographic RDT. Note: Ab=antibody, Au NP=gold nanoparticle.
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Most manufacturers guarantee device stabilities within
certain reasonable temperature ranges — recent WHO
analysis of commercially available malaria RDTs found
that 37 out of 50 tests claimed stability ranges of 2–30°C,
and that the remaining 13 tests claimed stability up to 40°C.
[18] However, in many countries, ambient temperatures
regularly exceed these limits. Studies tracking a shipment
of malarial rapid diagnostic tests to sites in Cambodia
found that devices were exposed to temperatures in excess
of 30°C for 28% of the time spent in transit and storage —
roughly 3,400 hours. Included within this sum were 44
hours during which temperatures soared to between 40 and
45°C. [19] Even these conditions, however, are mild in
comparison to the extremes typically seen in regions of sub-
Saharan Africa. In a study conducted in Senegal, devices
left at one site experienced temperatures in excess of 40°C
for 18% of the time, and were stored at over 30°C for 89%
of the time. Similar results were found in Ethiopia, where
devices in one site were stored at temperatures over 30°C
for 80% of the time. [18]
Extended exposure to these conditions has been linked to
reduced test sensitivities. One site in Brazil found that after
fifteen months’ storage under ambient conditions, RDT test
lines specific to the malarial species Plasmodium falciparum
(Pf)  and Plasmodium vivax  (Pv)  exhibited sensitivities  of
79.7% and 85.7%, respectively, which is much lower than
the 95% threshold recommended by the WHO. The authors
attributed this reduced performance to extended storage in
conditions outside of the recommended temperature range
— the average maximum daily temperature at which the
tests were stored was 29.4°C, with a range of 22.7 to 33°C. [20]
In  order  to  minimize  test  attrition  due  to  thermal
degradation,  successful  RDT  inventory  management
requires  close  coordination  between  manufacturers,
governmental  agencies,  couriers and regional  clinics,  to
provide seamless cold-chain continuity during the course
of  product  distribution  and  storage.  RDTs  should  be
handled by the same standards established for vaccines
and  therapeutics,  including  the  use  of  vaccine  vial
monitors  for  indicating  the  extent  of  thermal  stress  to
which  the  products  have  been  exposed.  [21]  Finally,  if
possible,  lot  performance  should be  tested regularly  to
detect potential product deterioration. [10]
Studies have been conducted into the use of evaporative
cooling boxes (ECBs), which passively maintain reduced
internal temperatures by harnessing the latent heat of
evaporation. In Cambodian field sites, researchers ob‐
served that the use of ECBs resulted in an average 97%
reduction in the number of hours Pf-specific RDTs were
stored above manufacturer limits (30°C), versus storage
under ambient conditions. As a result, the lifetime of the
RDTs stored in ECBs was extended from 210 days to 300–
360 days, depending on the location. [22] Similar results
were obtained in a study conducted in Afghanistan — Pv-
specific RDTs stored in a passive cooling device were
subject to temperatures that were, on average, 8°C cooler
than ambient conditions, and as a result tests were never
stored at temperatures greater than 30°C. This resulted in
a test strip invalidity rate of only 10%, as compared with
17% for RDTs stored under ambient conditions. [23]
The climates in which RDTs are deployed are also subject
to high humidity, which can impair device performance.
[24] In a survey of 50 commercially available malaria RDTs
and 11 HIV RDTs, it was found that almost all were
hermetically sealed and shipped with desiccant sachets, in
accordance with WHO guidelines. However, only 60% (30)
of the malaria RDTs and 45% (5) of the HIV RDTs were
observed to contain humidity-indicating dye, and of these,
all 30 malaria RDTs and three of the HIV RDTs were found
to contain the toxic dye cobalt dichloride, rather than the
preferred, more benign, methyl violet or iron salts. Less
than half of the products packed with self-indicating
sachets instructed users to check the colour of the silica
desiccant to assess test validity. [25] These changes —
universal inclusion of benign, self-indicating desiccants
and clear instructions for use — would serve to reduce the
risk of RDT invalidation by humidity.
2.2 Inadequate Characterization of Affinity Agents and Antigens
An additional technical issue that has potentially contrib‐
uted to the historically sub-optimal performance of
commercial RDTs is the use of poorly characterized
commercial antibodies that have not been optimized for
use in low-infrastructure settings or with complex biolog‐
ical samples. The most frequently used affinity agents are
monoclonal and polyclonal antibodies (both IgG and IgM),
and these immunoglobulins are typically supplied by
outside vendors removed from the RDT production
process. Thus, there has generally been little oversight into
commercial antibody development and the potential
failure modes that can occur during this procedure.
The generation of antibodies for diagnostics is a complex
undertaking. If a polyclonal mixture is being produced, the
process involves the inoculation of a large number of
animals with purified recombinant antigen and the
subsequent harvesting of the antibody pool from the
animals’ blood or (in the case of chickens) egg yolks, via
affinity chromatography. [26] One of the benefits of
employing polyclonal antibodies is that this purified pool
is likely to contain species exhibiting a distribution of
biophysical characteristics, providing redundancy if
individual clones should fail due to thermal denaturation.
[27] This pool is also composed of clones that cumulatively
recognize many antigenic epitopes, and this can result in
strong, polyvalent binding interactions. [28]
However, the traditional production process for polyclonal
antibodies is markedly imprecise, leading to the generation
of clones specific to serum components and impurities
within the original antigen preparation, as well as to
conserved antigenic epitopes observed in closely related,
environmental pathogens. This can result in reduced
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specificity if orthologues to the target antigen are ubiqui‐
tous, or if retained clones are specific to protein species
found in patient samples. Although negative selections
against known orthologues and host cell impurities can be
conducted in additional affinity chromatography [28] or
membrane purification [29] steps, the lack of clonal
characterization and the absence of sequence information
make direct manipulation of the polyclonal pool difficult.
Additionally, the production process can be inconsistent —
each new polyclonal pool is unique in its compositional
make-up, and thus batch-to-batch variability in perform‐
ance can be observed. [30]
In instances where antigen specificity and consistent
antibody properties are concerns, monoclonal antibodies
are employed in the place of polyclonal blends. Whereas
the production of polyclonal antibodies takes only a few
months, however, traditional monoclonal antibody
development can take up to a year, and is considerably
more costly. [31] Within this workflow, the lymphatic B
cells of inoculated animals are harvested and analysed with
single cell resolution, and the cell found to produce high-
affinity antibodies specific to the antigen of choice is used
in the creation of an immortalized hybridoma. This allows
for the consistent, indefinite production of a well-defined
clone exhibiting complementarity for a single antigenic
epitope. However, while this reduces cross-talk with
environmental protein species, it also introduces the risk
that the identified clone lacks the robustness necessary to
withstand the harsh conditions to which RDTs are exposed
in the field. Thus, the heat lability of developed monoclonal
antibodies should ideally be characterized via differential
scanning calorimetry or thermal incubation followed by an
immunoassay challenge. [32]
In addition, the reliance upon animal hosts for the produc‐
tion of antibodies raises concerns about whether the
purified recombinant antigen used in immunization will
present native, clinically relevant epitopes in vivo. The
chemical and biological environment in which an antigen
would naturally be detected in a patient’s sample is
potentially very distinct from the environment of an animal
host’s circulatory system. If these environmental differen‐
ces elicit structural changes in the antigen species, the
antibodies raised against it may not bind to the antigen in
clinical samples with equivalent affinity. For instance, in
the case of the malarial antigen histidine-rich protein 2
(HRP2), it has been shown that the secondary structural
elements of the native, haem-bound form are drastically
different from that of the unbound form. [33] Given the
abundance of free haem in animal serum, this likely has
little effect upon the suite of antibodies generated by the
host immune system, but for antigens found in other
peripheral fluids such as urine or sputum, structure-
altering interactions with fluid-specific ligands or other
chemical determinants may not be recapitulated in the host
circulatory system.
The imprecision of polyclonal antibody production, the
complexity of the monoclonal antibody identification
process, and the uncertainty involved in using live animal
immunization to generate antibodies provide the motiva‐
tion for the use of protein display technologies for the
generation of affinity agents. The methods most commonly
employed are phage [34] and yeast [35] surface display,
though in vitro techniques such as ribosome, mRNA,
covalent DNA [36] and liposome [37] display have also
been demonstrated. These methods are all founded upon
the idea of screening vast combinatorial libraries for
binding molecules, while maintaining a physical linkage
between phenotype (i.e., binding properties) and genotype
(i.e., the gene encoding a specific protein variant). Protein
display technologies allow for the isolation of high-affinity
binding molecules — immunoglobulins as well as non-
antibody scaffold proteins — within the span of a month,
enabling precise clonal characterization and straightfor‐
ward genetic manipulation. Successful selections have
been demonstrated against many targets, including
biomarkers for infectious disease [38], membrane proteins
[39] and whole cells [40]. Display technologies have also
been used to engineer affinity agents that exhibit greater
thermal stability. [41]
The use of these display technologies enables the genera‐
tion of monoclonal or oligoclonal binding molecules within
clinically relevant contexts. If made the industry standard,
this practice would allow for greater precision and control
in the development of commercial affinity agents for RDTs.
Well-characterized oligoclonal pools of binding molecules
are of particular interest, as they combine the specificity of
monoclonal binders with the increased stability of a
population of affinity agents. However, the mode of
antibody production is only one-third of the problem —
there are also technical issues to be addressed in the
sourcing of target antigens, as well as in the selection of
binding modalities.
Recombinant antigen sourcing is of utmost concern in the
antibody production process. In many cases, commercial
antigens  are  expressed  as  fusion  proteins  for  soluble
presentation [42], and the presence of this fusion partner
(e.g.,  SUMO,  NusA,  MBP,  GFP,  etc.)  can  result  in  the
generation of non-specific antibodies that can only be culled
via negative selections against the purified, solitary fusion
species. Protease cleavage techniques can be employed for
fusion tag removal following soluble protein expression, but
these processes tend to be inefficient. To date, the highest
cleavage efficiencies have been demonstrated by the SUMO
tag/protease system. [43] Another critical consideration in
the preparation of antigens for antibody generation is the
glycosylation state of the protein. If expressed in E. coli,
eukaryotic protein species will lack their native glycosyla‐
tion, and even eukaryotic expression systems such as P.
pastoris could potentially yield non-natural glycosylation
profiles.  [44]  Furthermore,  heterologous protein expres‐
sion systems have been shown to be subject to the forma‐
tion  of  insoluble  inclusion  bodies  [45]  and  the  mis-
incorporation of amino acids [46], both of which can result
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in misfolded products. Thus, the expression system used to
produce recombinant antigens must be chosen with careful
consideration  of  the  antigen’s  native  host,  and  protein
characterization  studies  (e.g.,  circular  dichroism,  size
exclusion chromatography, and mass spectrometry) should
be conducted prior to binder selection.
Increasing focus has also been given to the potential use of
non-immunoglobulin affinity agents in RDTs. Antibodies
are bulky macromolecules, which limits their effective
surface density upon immobilization and renders them
susceptible to non-specific binding by heterophilic anti‐
bodies and other blood factors. [47, 48] Immunoglobulins
have also been shown to be inherently unstable molecules,
losing binding activity following surface immobilization
even in ideal, refrigerated conditions. [49] Finally, they are
also subject to a restrictive intellectual property landscape,
which reduces the possibility of patent protection for
innovative antibody-based diagnostics. [50]
In order to circumvent these limitations, a number of
alternative affinity agents such as ankyrin repeat proteins,
single-domain camelid antibodies, oligonucleotide aptam‐
ers and shark immunoglobulins have been investigated for
use in diagnostic tests for HIV, [51] dengue, [52] tubercu‐
losis, [53, 54] and malaria. [55, 56] Given the innate ther‐
mostability and bio-orthogonality of these novel binding
scaffolds, it is expected that their use in commercial RDTs
could yield significant stability and specificity benefits in
comparison with antibodies. Accordingly, it is expected
that interest in their potential uses in diagnostic applica‐
tions will only continue to grow in coming years.
2.3 The Prozone Effect
An additional possible source of technical failure is the
prozone effect — the occurrence of false-negatives or
inaccurately low-intensity test lines as a result of 1)
overabundant antigens or 2) overabundant antibodies. In
the first case, unbound antigens may completely saturate
the test line, preventing the binding of antigen-conjugated
reporter complexes, and the development of a positive
signal. In the second case, antigens can become masked in
multivalent immune complexes, resulting in reduced
antigen binding at the test line. [57] This phenomenon was
found to be common within certain test formats — in a
study conducted upon HRP2-specific RDTs, 16 out of 17
tests demonstrated the prozone effect, although the same
study found that RDTs specific to parasite lactate dehydro‐
genase (pLDH, another malarial biomarker) yielded no
incidence of the phenomenon. [58] The effect only occurs
in samples exhibiting high parasitaemia, with more than
4% of red blood cells parasitized, and the incidence of the
prozone effect within these high-load samples ranged from
6.7–38.2%. [59]
A number of strategies can be employed to prevent the
occurrence of false-negatives due to the prozone effect.
Firstly, manufacturer recommendations on the appropriate
sample volume to be applied should always be followed,
as application of too large a volume can elicit the phenom‐
enon. [58] The prozone effect is also abated upon dilution
of the patients’ samples, and so for patients presenting
severe clinical manifestations of malaria, health care
workers can elect to verify a weak or negative test result
using a diluted sample. [60] Finally, the use of alternative
device architectures may prevent the occurrence of the
prozone effect. The Dual Path Platform is a novel immu‐
nochromatographic format in which the patient sample
and reporter antibodies are mobilized separately and
sequentially, and travel along distinct paths en route to the
test line. This allows for any antigens present in the patient
sample to bind to the capture antibodies prior to conjuga‐
tion with the reporter complexes, and thereby precludes
the possibility of prozone-mediated false-negative results.
[61]
2.4 Subjective Interpretation of Test Lines
By virtue of being targeted for use at the point-of-care,
immunochromatographic RDTs must be amenable to facile
and accurate interpretation by minimally trained opera‐
tors. However, test lines are often subject to highly variable
and user-dependent readings, which can be impacted by
user biases, low signal contrast, and inadequate training
materials. Additionally, tests can yield anomalous results
that can be difficult to interpret accurately, frequently
leading to erroneous diagnosis. [62] Over the course of the
WHO analysis of commercial malaria RDTs, a broad
variety of abnormalities were observed, ranging from
irregular migration of the fluid front that obscured faint
signals, to “ghost lines” in which test lines remained
uncoloured, and the background became heavily stained.
[63] In order to reduce the impact of these phenomena and
counter the subjective nature of visual evaluation, devel‐
oped tests should be read by multiple independent
interpreters, and the level of agreement assessed. [64]
A number of additional strategies have also been proposed
for reducing inter-user variability in test interpretation.
Firstly, package inserts must include clear examples of all
potential test outcomes, particularly in the case of multi‐
plexed assays, and must address the appropriate course of
action to take upon the development of faint test lines. [15]
Universal training materials should also ideally provide
case studies by which the accuracy of operators’ interpre‐
tations can be tested. [65]
It has also been suggested that, given the ubiquitous
presence of camera phones, cellular devices could be
leveraged as a means of relaying test results to centralized
laboratories, where they could be digitally processed and
analysed by trained technicians. [66] This would not only
serve to reduce local operator error in test interpretation
and enhance test sensitivity, but could also provide
valuable epidemiological information to regional clinics.
However, a number of possible issues exist with this
approach, including the digital transmission of sensitive
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personal medical data, the potential for incompatibility
with the camera phone interface owing to the diverse and
varied nature of RDTs, and possible test-to-test variability
due to local lighting conditions and user practices. [61]
Interpretation of test results may also be facilitated by a
reduction in the background signal, either by de-colouring
patient samples, as has been demonstrated with whole
blood, [67] or by preventing non-specific adsorption of
patient sample components to the test membrane. System‐
atic studies of the effects of membrane materials and
porosity upon non-specific adsorption and the develop‐
ment of background signal are much needed, as non-
fouling RDT materials could make a considerable
difference in device performance. [68] Finally, while the
method has not yet been adapted to the RDT format,
polymerization-based amplification shows promise for
allowing the development of high-contrast test results. The
entrainment of phenolphthalein in nascent polymer thin
film yields an intense purple signal upon basic treatment,
and this has been shown to create a stark contrast, with low
background signal. [69]
2.5 Time-Dependence of Signal Development
Test performance can also be negatively impacted by the
interpretation of tests after the recommended time period
for incubation has elapsed, or the archiving of tests for
future reference, both of which can lead to the development
of false-positive results. This delayed test line development
likely occurs due to the upstream migration of free reporter
conjugates and cross-reacting blood elements from the
absorption pad — termed “backflow” — and their non-
specific adsorption to the test line. [70] Manufacturers
generally include recommended timelines for test devel‐
opment in the product literature, but these guidelines may
not be heeded if instructions are unclear, timing devices are
in short supply, or regional clinics are understaffed and
clinicians are otherwise occupied.
Several solutions to this problem have been proposed. In
situations where camera phones are available, digital
archiving of test results obviates the possibility of further
post-test development. Modular RDT configurations have
also been demonstrated, allowing for lateral flow test
elements to be snapped into place, and for the physical
isolation of the test line from the remaining sample bolus
following signal development. [71] Additionally, the
strategic inclusion of evaporation windows in the cassette
housing surrounding the absorption pad can reduce the
incidence or extent of back-flow. [72] Finally, alternative
methods of signal amplification which do not rely upon the
optical concentration of bulky nanoparticles may serve to
reduce the potential for non-specific adsorption of colloidal
reporter conjugates to the test line, and allow the further
development of archived samples.
Polymerization-based amplification has been proposed as
a means for the temporal discretization of test line devel‐
opment. Within this system, reporter antibodies are
coupled to small molecule photoinitiators rather than to
gold nanoparticles. Photoinitiators trigger a rapid chemical
reaction upon exposure to visible light, yielding a poly‐
meric thin film from aqueous monomer species within
seconds, and the film is visible to the unaided eye. The
discrete nature of this signal amplification process, con‐
trolled by a pulse of light, eliminates the potential for
extended test line development, and the initiator-coupled
reporter antibody may exhibit a reduced propensity for
non-specific adhesion to the nitrocellulose membrane in
comparison with antibodies coupled to bulky nanoparti‐
cles, which can become entrained in viscous samples such
as sputum or saliva. [69, 73]
2.6 Insensitivity to Low Disease Loads
The technical challenges discussed in the preceding
sections, in combination with a number of biological
determinants, are implicated in the modest limit of detec‐
Figure 2. Malaria RDT anomalies encountered in production lots. Figure reproduced with permission from reference 63.
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tion demonstrated by many RDTs, which renders them
insensitive to low pathogen/antigen loads. This shortcom‐
ing represents a significant challenge to the diagnostic
format and reduces its potential utility in elimination
programmes, in populations exhibiting inherently low
pathogen loads, and in patients seeking diagnosis during
critical, quiescent stages of the pathogen life cycle. [74] In
the case of malarial RDTs, the WHO requires a panel
detection score of 75% at a parasitaemia of 200 parasites/µl
in order for the product to warrant endorsement. [16]
However, the threshold for pyrogenic onset has been
shown to vary from 10 to 200,000 parasites/µl, with 22% of
patients developing their first acute fever at a parasite load
below 200/µl. [75] Thus, even for the select assortment of
commercial malaria RDTs demonstrating compliance with
WHO standards, sufficiently low limits of detection have
not been demonstrated for the early and accurate diagnosis
of nascent infections, or of asymptomatic carriers.
Validating the need for lower limits of detection in RDTs,
one study of healthy Gabonese adults with no febrile
symptoms found that more than half of participants
nonetheless tested positively for P. falciparum malaria via
nested polymerase chain reaction (PCR). [76] These
samples were then tested by RDT, using a product with an
80% panel detection score from the relevant round of WHO
product testing, [77] and the RDT sensitivity using PCR as
the reference standard was observed to be only 46%. In all
cases of a false-negative result, the parasite load was
observed to be 100/µl or less, demonstrating the inadequa‐
cy of RDTs when operating at these levels.
Several methods have been developed to improve the
inherent limits of detection for diagnostics, many of which
could find eventual application in commercial RDTs. One
group has recently demonstrated the use of a simple pre-
processing step to concentrate the malarial antigen HRP2
prior to RDT application, resulting in a four-fold signal
increase and a limit of detection as low as three
parasites/µl. [78] A similar process has been used to
concentrate tuberculosis bacilli in sputum using magnetic
nanoparticles. It has been proposed that this method, used
in conjunction with a lysis protocol, could be used to locally
concentrate intracellular biomarkers. [79, 53] This approach
may also prove fruitful in the diagnosis of enteric fever and
human African trypanosomiasis, as both diseases require
pathogen concentration for sensitive detection. [80]
Alternative device architectures have also been considered
for enhancing the limits of detection for RDTs. Immuno‐
chromatographic formats incorporating multiple input
streams are claimed to increase test sensitivity by allowing
patient antigens to form stable binding interactions with
the capture antibodies prior to being bound by reporter
complexes. This reduces the incidence of multiple antigens
binding to single reporter antibodies, and allows for test
line saturation. Examples of these novel formats include the
previously mentioned Dual Path Platform and three-
dimensional stacking flow architectures. [61, 73] Finally,
the functionalization of glass slides with non-fouling
“polymer brushes” has been shown to greatly reduce the
level of non-specific adsorption in immunoassays, yielding
femtomolar limits of detection in complex media. [68] If
adapted for use in an immunochromatographic format, this
technique could potentially render RDTs capable of
playing a key role in elimination campaigns and early case
detection.
Additionally, the identity of the bio-conjugates employed
in immunochromatographic assays impacts the inherent
test sensitivity — in a comparison between four different
reporter conjugates, it was found that carbon black nano‐
particles exhibited the lowest limit of detection by an order
of magnitude. [81] RDTs based upon cellulose nanobeads
have also been shown to yield higher sensitivity than those
based upon colloidal gold reporters, due to the increased
surface-area-to-volume ratio of the cellulose particles, and
the greater degree of optical contrast afforded by the
incorporation of dye molecules into the nanobeads’ porous
structure. [82] The use of immunoliposomes has also been
shown to drastically improve the limit of detection, due to
the liposomes’ ability to internalize high concentrations of
absorbent or fluorescent dyes. [83] Other labelling candi‐
dates that may improve test sensitivity include silica
nanoparticles, quantum dots, silver-enhanced colloidal
gold, magnetic nanoparticles, dendrimers and carbon-
based structures such as nanotubes and colloidal carbon
black. [84]
Finally, efforts to optimize the paratopic stability and
orientation of surface-bound affinity agents may yield
lower limits of detection, by increasing the proportion of
active capture agents participating in the biorecognition
event. One approach to improving surface-bound reagent
stability involves the addition of a disaccharide such as
sucrose or trehalose to the protein formulation during
lyophilization. This results in the formation of an amor‐
phous sugar matrix which places conformational con‐
straints upon the embedded proteins, thereby preserving
the integrity of critical paratopes. [85] Recent studies have
also demonstrated the use of multivalent display platforms
— such as lyophilized surface-displaying yeast cells and
self-assembled protein particles — for the stable, preferen‐
tially oriented presentation of capture agents. [86, 87] These
approaches may enhance the intrinsic activity of immobi‐
lized test line reagents, rendering RDTs more sensitive to
low disease loads.
2.7 Unsuitability for Pathogen Quantitation
A further technical issue facing RDT manufacturers is the
growing desire within the medical community for quanti‐
tative or semi-quantitative diagnostic results. The ideal
diagnostic test would allow accurate quantification of a
patient’s pathogen load, as this information would enable
clinicians to make more informed treatment decisions
based on knowledge of the probable stage of disease
progression or its measured response to therapeutic
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treatment. Thus far, commercial RDTs have been strictly
binary, the antigen being either absent from a patient
sample or present to an arbitrary degree. Studies have
shown, however, that test line intensity can be loosely
correlated with antigenaemia, [16] particularly if fluores‐
cent reporter species such as dye-loaded liposomes are
used. [88] At the expense of introducing equipment and
technical infrastructure, the use of digital image processing
could allow for semi-quantitative analysis of these RDT
results in centralized medical centres. [89] Additionally,
titrations of increasing antibody concentrations immobi‐
lized on membrane surfaces in a bar code pattern might be
used as a semi-quantitative measure for bracketing antigen
levels. [90]
Ultimately, however, RDTs are antigen tests, and thus in
order for any quantitative or semi-quantitative measure of
RDT signal output to be of clinical utility, the concentration
of the antigen in the patient sample must correlate with the
actual pathogen load. A number of studies of the malarial
antigen HRP2 have attempted to model this relationship
both in vitro and in silico, and have claimed that its concen‐
tration in patient samples can be approximately correlated
to malarial parasitaemia, even in cases where the bulk of
the pathogen load is sequestered within the patient
capillary system. [91, 92] However, it has been shown in
patient samples that the same level of parasitaemia can
result in drastically different plasma concentrations of
HRP2. [93] This might be due to differences in the life cycle
stage between different samples, holdover of HRP2 from
previous infection, immunocomplexing of the antigen, or
even just stochastic effects in the productivity rates of
different parasite populations.
Molecular diagnostics such as NAATs and quantitative
PCR may allow for the straightforward quantitation of
actual disease load due to the direct proportionality
between gene representation and pathogen levels. It must
be noted, however, that even molecular quantitation is
complicated by the possibility of pathogen sequestration or
latency, in which case pathogen loads would be underes‐
timated. [76] Ultimately, protein expression levels have
proven difficult to reliably relate to pathogen loads, and
thus even if RDTs are made suitable for the approximate
quantitation of antigen levels in patient samples, these
results may not allow the accurate quantitation of the
associated disease load for reasons relating to the underly‐
ing biology of the infectious agent and the host response.
3. Biological Barriers
These technical complications must be overcome in order
for immunochromatographic RDTs to consistently demon‐
strate a high degree of test sensitivity. However, the
mechanics of test operation are only one part of the problem
— the performance of an RDT is inherently limited by the
quality of the disease biomarkers that it is designed to
detect, as well as by the nature of the sample with which it
is being challenged. These biological issues contribute to
poor device performance, and represent barriers to the
realization of sensitive and specific rapid diagnostic tests.
3.1 Non-Ideal Biomarkers
Much as the ideal rapid diagnostic test would fulfil
ASSURED criteria, the ideal infectious disease biomarker
to be targeted by an RDT would also meet a distinct and
exacting set of benchmarks. We propose that the ideal
biomarker must be:
• Specific (to the pathogen as well as to the particular
species or serotype)
• Abundant (to a degree sufficient for detection, at all
pathogenic loads, and during all stages of pathogen life
cycle)
• Stable (thermally and chemically, and reliable)
• Quantitatively meaningful (indexed to pathogenic load
to allow estimation of disease severity and tracking of
therapeutic effect)
• Universal (in both expression and structure, geographi‐
cally and amongst patients of all ages, genders, ethnic
backgrounds and immune states)
• Accessible (in peripheral fluids of all patients, regardless
of age, immune status or prior infection, and without
sample pre-processing or concentration)
• Timely (observed in early stages of infection and
eliminated quickly upon pathogen clearance)
• Characterized (well-understood physiological role,
structure and dynamic profile)
• Heterologously expressible (in context-relevant form for
facile generation of binding molecules and for use in
assay development as a positive control)
By  examination  of  the  suite  of  biomarkers  currently
targeted  by  RDTs,  it  becomes  evident  that  biomarkers
fulfilling all of these SASQUATCH criteria are rare. In the
case of malaria,  HRP2 is absent within sub-populations
in Peru and Brazil, and has highly heterogeneous primary
sequence  (not  universal).  [94–96]  HRP2 also  persists  in
the bloodstream for up to a month after parasite clear‐
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ance  (not  timely),  [97]  and  its  accurate  heterologous
expression  is  difficult  due  to  the  potential  for  absent
glycosylation motifs and amino acid substitution. [98, 46]
HRP2 is, however, present in abundance, accessible in the
patients’  bloodstream,  thermally  stable,  and  highly
specific to P. falciparum,  and in this way it  meets some
benchmarks of ideality. [97]
In  another  example,  lipoarabinomannan  (LAM)  is  a
lipopolysaccharide  associated  with  the  cell  wall  of
Mycobacterium tuberculosis  (Mtb).  It  is  heat stable,  found
in  urine  samples  and specific  to  active,  but  not  latent,
tuberculosis.  However,  LAM  is  not  a  protein  species,
which prevents its facile heterologous expression, and it
features a conserved mannan core that is also observed
in similar cell wall derivatives from environmental, non-
pathogenic species of  Mycobacterium.  This is  thought to
result  in  cross-reactivity  in  RDTs,  negatively  impacting
the  biomarkers’  specificity  for  Mtb.  Furthermore,  the
sensitivity  of  LAM-based  tests  has  proven  to  be  poor,
because  the  concentration  of  LAM  in  patient  urine  is
strongly dependent upon the patient’s immune status. In
non-immunocompromised  patients,  LAM  is  bound
within large immune complexes, preventing its passage
through the renal  glomerular  basement  membrane into
the  patient’s  urine.  It  is  only  in  severely  immunosup‐
pressed patients that LAM is detected with any sensitiv‐
ity,  and  thus  the  biomarker  is  considered  to  be  of
diagnostic  utility  only  for  HIV-positive  individuals.
However,  even at  CD4 counts  of  ≤50  cells/µl,  reported
test sensitivities are only 66.7%. Thus, a LAM-based test
would at best serve only as an opt-in test for determin‐
ing which patients have a high likelihood of harbouring
tuberculosis. [99, 100]
In a third and final example, NS1 is a well-characterized
biomarker of the dengue virus. It is a structural protein
amenable to heterologous expression, it is present in
abundance in patient serum during the first nine days after
the onset of symptoms, and it is 100% specific to dengue
infections. However, NS1 is of greater diagnostic utility for
primary dengue infections than for secondary infections, as
it becomes complexed by circulating host antibodies
during secondary infections. This phenomenon decreases
the sensitivity range of dengue RDTs from 94.7–98.3% for
primary infections to a range of 67.1–77.3% for secondary
infections. [101] This decrease in sensitivity represents a
considerable health challenge, as secondary dengue
infections can manifest as much more severe illnesses
requiring more urgent and concerted care, such as dengue
haemorrhagic fever and dengue shock syndrome. It is
thought that this same phenomenon occurs in the case of
the malarial antigen HRP2, with the host humoural
immune response causing the sequestration and degrada‐
tion of the HRP2 antigen. [102]
In order to improve test sensitivities when dealing with
non-ideal biomarkers, manufacturers of RDTs often seek to
use the multiplexed detection of distinct, species-specific
antigens. In the case of malaria, RDTs are often multiplexed
to detect HRP2 and the P. vivax variant of parasite lactate
dehydrogenase (Pv-pLDH), to distinguish between
infections by P. falciparum and P. vivax. Alternatively, tests
can be multiplexed to select for Pf-pLDH and HRP2, which
yields highly sensitive indications for falciparum malaria.
[16] Multiplexed RDTs have also proven to be efficacious
in discriminating between distinct diseases with non-
specific symptomatic presentations. One recent study
demonstrated the use of multicoloured nanoparticles to
distinguish between three febrile illnesses — yellow fever,
Ebola and dengue fever — with minimal non-specific
signal development. [103] Finally, in dengue diagnosis, test
sensitivity has been shown to be greatly improved by the
multiplexed detection of NS1 with anti-NS1 IgG and IgM
host antibodies, with sensitivity increasing from 69.2% to
93.0%. [104]
Figure 3. Multiplexed detection using silver nanoparticles (AgNPs). a)
Antibodies to viral proteins are printed on the individual detection areas. A
mixture of AgNPs conjugated to anti-dengue NS1, anti-Ebola GP, and anti-
yellow fever NS1 antibodies is deposited in the conjugate pad. When each
of the infectious disease biomarkers is detected, the corresponding AgNPs
form a coloured band at the specific line. b) Capture antibodies are combined
and printed into a single test line, which produces a band of a different
colour depending on the antigen detected within the sample. YFV: ornage;
EV: red; DENV: green. Figure reproduced with permission from Reference
103.
For many diseases, however, such antibody tests — that is,
the use of a pathogenic protein in a test line to detect anti-
pathogen host antibodies — are the only option currently
available for RDT-based diagnosis, due to the lack of
abundant, disease-specific biomarkers. This serological
diagnosis is the standard for a broad diversity of diseases,
including but not limited to HIV, chikungunya, leptospi‐
rosis, brucellosis and enteric fever. However, serological
diagnosis is subject to a number of problems. Firstly, it is
only an indirect means of diagnosing infection, as it uses
the host immune response as a proxy for direct pathogen
detection. As a result, serological tests yield a less reliable
sense for pathogen burden, and only yield highly sensitive
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results if the targeted host antibodies are specific to a
particularly immunogenic pathogen biomarker. Addition‐
ally, the time course of development for the host immune
response can be variable — IgM antibodies for chikungu‐
nya infections only emerge one week into the course of
illness, for instance, rendering RDTs useless until disease
symptoms are fairly advanced. [80]
Serological  tests  can  also  exhibit  low  specificity.  For
instance,  in  the  diagnosis  of  leptospirosis,  the  protein
used to target anti-pathogenic IgM antibodies is a whole
cell  antigen  prepared  from  a  non-pathogenic  strain  of
leptospire. Given the ubiquitous nature of non-pathogen‐
ic  leptospires  encountered  environmentally  (e.g.,  while
farming),  many  patients  may  have  already  developed
IgM antibodies to this antigen despite not harbouring a
pathogenic infection, and this can result in cross-reactiv‐
ity. [80] Additionally, the persistence of antibodies in host
circulation  (particularly  IgG  antibodies)  can  result  in
false-positive  results  after  primary  infection,  which
renders serological tests detecting IgG antibodies useless.
False-negative  results  are  also  common  when  serologi‐
cal  tests  are  used for  the diagnosis  of  immunocompro‐
mised patients. [28]
In order for the next generation of rapid diagnostic tests to
see the sort of proliferation and widespread use observed
in malaria RDTs, the identification of a new suite of disease
biomarkers is essential. Efforts to identify abundant,
disease-specific protein species accessible in the peripheral
fluids of patients are underway for many infectious
diseases, using sensitive “omics”-based methods to detect
pathogen-specific signals in noisy biological systems. [105]
For instance, multiple groups have recently used a high
performance liquid chromatography-mass spectrometry
workflow to identify tuberculosis-specific protein antigens
in patients’ urine. [106, 107] If these antigens can be used in
a multiplexed fashion for the sensitive and specific detec‐
tion of active TB, it would allow for confirmatory RDT
analysis of individuals incapable of producing sputum,
such as young children and immunocompromised pa‐
tients. It would also allow testing to occur without the
production of potentially infectious bio-aerosols, which are
hazards typically associated with sputum-based tests. [99]
3.2 Lack of Biomarkers/Drug Resistance
In a novel approach, several groups have also explored the
potential of using probe molecules — “synthetic biomark‐
ers” — as a means of interrogating the patient’s disease
state when ideal endogenous biomarkers are absent. One
study demonstrated the use of thrombin-sensitive nano‐
particles, which release ligand-encoded reporter molecules
upon cleavage by the up-regulated proteases passively
encountered in tumour tissues. These free reporter com‐
plexes are concentrated in the patient’s urine, and can
subsequently be detected by a paper-based immunochro‐
matographic test. [108] An analogous, albeit less invasive,
approach demonstrated the use of rational structural
design principles to construct a synthetic fluorogenic probe
that becomes activated upon cleavage by the Mtb-specific
enzyme, BlaC. While this cleavage product was not
reported in the context of an RDT, the study makes similar
use of exogenous biomarkers in lieu of host or pathogen
biomarkers. [109]
This synthetic biomarker approach may prove useful not
only for indicating the presence of pathogens for which
ideal native biomarkers have not yet been identified, but
also for probing the drug resistance of these pathogens. If
this drug resistance is affected by the activity of an enzyme
that degrades a front-line antibiotic (such as a cephalospor‐
in or β-lactamase), this enzymatic activity can be reported
by way of a cleavable probe, which, as in Reference 108, is
only accessible in peripheral patient fluids in its free state.
The use of small molecule probes as reporters of antibiotic
resistance have been demonstrated, [110] and if this
approach for detecting drug resistance proves successful,
it could address one of the key arguments levelled against
RDTs by proponents of molecular diagnosis.
3.3 Cross-Reactivity in Complex Fluids
Another biological factor potentially contributing to the
variable performance of rapid diagnostic tests is the
potential for non-specific cross-reactivity between the test
antibodies and elements found within complex biological
samples. In validation of this idea, the WHO’s fifth round
of malarial RDT evaluation included a study in which
products were challenged with blood samples that had
been spiked with potentially cross-reacting compounds
that might be observed in patient samples: anti-rheumatoid
factors, nuclear antibodies, anti-mouse antibodies and
rapid plasma reagin. While eight of the 42 products tested
showed no cross-reactivity whatsoever, the remaining 34
products showed cross-reactivity to at least one of the
compounds, to variable degrees. Anti-mouse antibodies
posed the greatest challenge, leading to the development
of false-positive results in all 34 cross-reacting products,
followed by rheumatoid factors (29), anti-nuclear antibod‐
ies (26) and rapid plasma regain (15). [16]
A number of strategies have been proposed to reduce the
incidence of these off-target reactions. As previously
mentioned, negative selections against whole blood or
cross-reacting compounds can be conducted to remove
promiscuously binding antibodies from a polyclonal pool.
[29] Additionally, buffer formulations can be specifically
designed for the inactivation of certain contaminating
elements of the patient sample. [111] Finally, the use of the
aforementioned bio-orthogonal affinity agents may
drastically reduce this cross-reactivity, by presenting
reduced molecular footprints and protein epitopes to
which host antibodies would not display complementarity.
4. Social Barriers
In the early stages of RDT development, the absence of
harmonized regulatory oversight led to the proliferation of
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so-called “backyard” manufacturers, [14] and as a result,
RDT markets became diluted with inexpensive, sub-
optimal products. The prevalence of these low-performing
devices has eroded the credibility of RDTs among health
care workers and within the broader communities they
serve, and has also complicated efforts to connect these
communities with validated, higher-quality RDTs that
come at a higher cost. As a result, there exist a number of
social and economic barriers to the successful, widespread
integration of high-performing RDTs into the diagnostic
landscape.
4.1 Non-Compliance with Negative RDT Results
As with any new health technology, manufacturers and
global health practitioners must work to educate the user
base about RDTs, and must endeavour to correct any
misconceptions that might have emerged over the past
decade of technological development. In a study conducted
in an area of Kenya where malaria RDTs were just being
introduced as part of a pilot programme, the authors found
that one of the primary challenges facing RDT introduction
efforts was patients’ poor adherence to negative RDT
results. In regions where febrile illnesses have historically
been presumptively treated as malaria, a negative RDT
result can inspire incredulity, especially if community
regard for modern medicine is unfavourable, or if patients
are unfamiliar with, or distrustful of, the new test format.
Consequently, patients receiving negative results by RDT
were often seen to self-medicate despite those results,
purchasing single-drug anti-malarials over the counter at
local pharmacies, or using medicine leftover from previous
infections. [112]
This suspicion of negative test results is shared by local
health care workers, as well — a study in Uganda found
that while 92% of clinicians believed that a positive malaria
RDT result was sufficient confirmation of a malarial
infection, only 49% believed that a negative RDT result was
sufficient grounds to rule out the disease. [113] This
reluctance to withhold anti-malarial treatment on the basis
of an RDT result is particularly pervasive when dealing
with children. In Zambia, 68.6% of febrile children with
negative malaria RDT results were nevertheless prescribed
the expensive artemisinin combination therapy (ACT)
Coartem®. [114] Cohort studies have validated the safety
of withholding anti-malarials from children, based on the
high negative predictive value of RDTs. [115] However,
health care workers’ preconceptions and the perceived risk
of a false-negative outcome still leads to habitual over-
prescription of medications.
4.2 Non-Adoption due to Cultural Determinants
In many cases, social and cultural factors deterred individ‐
uals from submitting to RDTs at all. In a study conducted
in two rural communities in Cote D’Ivoire, only 34 out of
100 self-presenting patients agreed to an RDT, and post-
evaluation interviews found that this aversion was attrib‐
utable to a variety of cultural determinants. Some patients
were reluctant to submit to RDT analysis for fear that they
were secretly being tested for more stigmatized illnesses,
such as HIV. [116] This mentality was particularly preva‐
lent in communities where malaria and HIV RDTs were
concurrently available. Other patients declined RDT
analysis on religious grounds, citing the sacred nature of
blood, and a preference for traditional diagnosis and
treatment, which are thought to address both the physical
and spiritual aspects of the disease without requiring blood
to be drawn.
In order to address these negative perceptions, it is essential
that locally and culturally relevant programmes of infor‐
mation distribution, education, and counselling be enacted.
The value of such programmes can be seen in the starkly
contrasting response of well-informed communities in
Ghana, where 98% of caregivers expressed a preference for
malaria RDT-based case management of their child’s
febrile illness over presumptive treatment, even acknowl‐
edging that a negative result would mean that ACTs would
not be prescribed. This high level of acceptance within the
community was predicated upon an understanding that
RDT use provides health workers with critical information
that fundamentally guides and improves their treatment
strategy. [117]
5. Infrastructural Barriers
The lack of general health education is a symptom of
broader societal problems, namely a dearth of qualified
health care workers and an underdeveloped medical
infrastructure. These insufficiencies can lead to product
misuse and supply interruptions, both of which serve to
degrade product credibility and reduce its potential for
impact in local communities.
5.1 Inadequate Training and Instructions
Though the device format is designed for use by individu‐
als with minimal formal training, general literacy and an
understanding of basic scientific principles are required for
appropriate test administration. If RDTs are used in self-
testing scenarios by patients lacking these skills, or admin‐
istered by primary health workers unfamiliar with proper
RDT usage practices, tests may be misused, leading to
misdiagnosis or outright test failure, and the erosion of
consumer confidence. [62, 111, 118] However, for health
care practitioners demonstrating basic medical skills and
provided with formal training, successful implementation
of RDTs does not appear to be dependent upon the
technician’s inherent skill level. In Bangladesh, highly-
trained laboratory technicians and less experienced field
technicians demonstrated roughly equivalent performance
in using dipsticks to test for cholera, [119] and local
community health workers in Uganda were fully capable
of satisfactorily administering RDTs and making diagnos‐
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tic judgments for malaria and pneumonia following an
eight-day training session. [120]
In order to facilitate the successful adoption of RDTs by
health workers, instructions and package labelling must be
clear, consistent and available in a range of relevant
national languages, especially English, French, Spanish
and Portuguese. [15] As much as possible, device design
and usage should be harmonized between different
manufacturers, to provide for greater ease-of-use and to
reduce the potential for confusion or improper application.
Where possible, instructions should be supplemented with
clear pictorial representations, and general guidelines for
proper RDT implementation should be translated and
made widely available by international coordinating
bodies such as the WHO. [62]
5.2 Supply Chain Disruption
Another infrastructural barrier impeding the widespread
adoption of RDTs in global health practices is the frequent
occurrence of supply chain disturbances in underdevel‐
oped medical systems, and the significant impact these
perturbations can have upon the availability of high-
volume consumables such as RDTs. Health care workers
cite this supply disruption as a deterrent for establishing
RDTs as a cornerstone of their diagnostic programmes.
[112] Cross-sectional studies conducted at 15 health centres
across Mozambique illustrate the scope of the problem,
documenting significant lost malaria RDT consumption —
as a percentage of the monthly usage rates — due to
product stock-outs. These lost consumption rates ranged
from 0–149%, with the weighted average being 78% (i.e.,
the number of patients who were not served with an RDT
due to stock-out was, on average, equal to 78% of the
monthly number of patients who were served). [121]
These sporadic supply interruptions were attributed to
several key drivers: 1) unrealistically optimistic expecta‐
tions of the lead times required to receive new shipments
at regional levels, 2) a failure to sufficiently prepare for
seasonal increases in malaria RDT consumption and the
increased difficulty of navigating flooded roads to deliver
shipments, and 3) inadequate local compliance with local
inventory management practices. These elements were all
considered symptomatic of a broader, systemic problem —
poor leadership at the national level and a resultant lack of
standardization and timely communication between
different levels of the supply chain. In order to decrease
gaps in coverage due to supply fluctuations, international
agencies such as the WHO must model and facilitate good
practices in high-level resource allocation, and in coordi‐
nation with national agencies and commercial suppliers.
6. Regulatory Barriers
The establishment of universal regulation and a standard
process for RDT evaluation is critical for preventing
markets from being subject to the sort of uncontrolled and
unquantified product heterogeneity that has slowed the
uptake of malaria RDTs over the course of the last decade.
While indicators of manufacturing compliance such as the
CE-IVD mark are important, they are more administrative
measures than measures of product quality. Rather,
procurement decisions should be based upon the endorse‐
ment of the WHO, which is founded upon active assess‐
ment of test performance. By playing an active and visible
role in endorsing products for countries seeking RDT
supplier contracts, the WHO can help to incentivize
manufacturers to submit their products for evaluation and
to price high-quality products competitively for the
market.
6.1 Product Evaluation
A model for this successful market intervention exists in
the WHO’s exhaustive assessment of available malaria
RDTs. From 2008 to the present, the WHO completed five
rounds of malaria RDT evaluations, and the results
suggested a broad spectrum of device performance. In
testing rounds 2–5, only 65.6% (86/131) of products
featuring P. falciparum-specific test lines performed within
WHO specifications, with 34 products demonstrating
panel detection scores (PDS) below the 75% threshold at
200 parasites/µl, and a further 11 tests demonstrating
unacceptably high false-positive rates, greater than 10%.
Similarly, only 42% (42/100) of P. vivax-specific test lines
met WHO standards, with 56 products failing on the
grounds of low panel detection scores, and an additional
two products demonstrating false-positive rates greater
than 10%. In combination products that claimed to test for
both species, only 31 out of 77 products met recommended
procurement criteria for both species; 32 products only
achieved a satisfactory PDS for one of the two species, and
14 products failed to meet specifications for either species.
In total, only 44.3% (59/133) of products met WHO specifi‐
cations for all relevant test lines: 25 Pf-only products, and
34 combination Pf-Pv products. [63]
In collaboration with the Foundation for Innovative New
Diagnostics (FIND), the WHO has established a searchable
database [122] that allows users to screen these malaria
RDTs by setting acceptable thresholds for performance
metrics (PDS, maximum false positivity rate, maximum
invalid test rate, etc.), and directly comparing the perform‐
ance of tests that meet those criteria. Tools such as these are
critical for informing the choices of national and regional
control programmes, and in the future, these objective
presentations of RDT performance should ideally be made
widely available for all emerging disease targets. With
expanded availability of reliable information and context-
appropriate recommendations, [17] governments should
be able to requisition RDTs based on programmatic needs,
rather than being limited by cost or historical practices. [78]
As tests for new disease targets such as dengue, enteric
fever and visceral leishmaniasis begin to achieve significant
market penetration in coming years, the WHO’s experience
in successfully conducting assessments of malaria RDTs
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must be leveraged. These new tests will come from a variety
of manufacturers, and will necessarily demonstrate a broad
range of performance characteristics. For instance, in 2013,
seven dengue RDTs were available on the market, and
reports of their sensitivity and specificity already varied
wildly, with ranges of 48.5–98.9% and 73.8–100%, respec‐
tively. [80] In order for these new RDTs to gain the confi‐
dence of the global health community, and in order for the
scarce financial resources of national health agencies to be
put to good use, emergent RDTs require the same sort of
rigorous evaluation and validation afforded to malaria
RDTs. [123]
6.2 Establishing Testing Standards
The shrinking operational budgets of the WHO diminish
the possibility of running evaluation campaigns similar in
scale to the malaria RDT trials for each new disease target.
Instead, the WHO must focus upon standardizing studies
conducted in academic, commercial and governmental
labs, releasing guiding documents for study design [124]
and exercising oversight on the conduct of these studies
prior to accepting third-party results into composite data
sets. Critical study design elements that warrant confirma‐
tion include the use of appropriate study groups in high-
prevalence settings, comparison against an appropriate
reference standard test and the conduct of appropriately
blinded evaluations with adequate sample sizes. [123]
The establishment of universal reference standards are a
point of particular concern, as many “gold standard”
assays also suffer from sub-optimal sensitivities and
specificities, and may not be practical in rural, endemic
regions. For instance, the gold standard assay for the
diagnosis of visceral leishmaniasis is the microscopic
examination of splenic aspirates. While this technique
yields adequately high sensitivities ranging from 93.1–
98.7%, the procedure is complex and highly invasive,
requiring well-equipped medical facilities, trained and
dedicated medical workers, and cooperative patients
without demonstrable health complications. [13] In a case
such as this, it would be infeasible for studies evaluating
the performance of RDTs in endemic settings to use this
diagnostic test as a basis for comparison, despite its being
the most sensitive option available.
Thus, in order for the WHO to establish common standards
across all evaluative studies for a given disease, consider‐
ation must be given not only to the performance of that
diagnostic format, but also to its practicality and accessi‐
bility. If standards are to be established which are logisti‐
cally prohibitive for rural settings, this must either be done
at the conscious expense of RDT evaluation in those
endemic regions, or the infrastructural and collaborative
groundwork must be laid to enable local study facilitators
to comply with these standards.
6.3 Quality Assurance
An additional challenge to the RDT platform that merits
regulatory action is the need for mandatory quality
assurance programmes and on-site lot evaluations. Signif‐
icant lot-to-lot variation in malaria RDT performance has
been observed, [1] possibly due to changes in manufactur‐
ing practices, membrane sourcing, or the batch of polyclo‐
nal antibodies used. To address this issue, the WHO and
FIND currently offer free testing of malaria RDTs, and all
parties — including manufacturers, centralized national
distribution centres and rural clinics — are encouraged to
submit samples for analysis. These RDT lot samples are
maintained under conditions similar to those potentially
encountered in the field and tested repeatedly throughout
the lifetime of the product, in order to track any deteriora‐
tion in product performance. [125] Although many suppli‐
ers do participate in the programme as part of a policy of
continual process monitoring and improvement, use of
these services is not mandated for WHO-endorsed manu‐
facturers. Therefore, it is unclear how widespread this
practice is, as well as whether participation in lot testing is
broadly publicized.
As the RDT landscape develops for new disease targets, the
continued expansion of these distributed RDT lot-testing
capabilities is essential. It would also be of benefit to public
health programmes to make WHO product endorsement
contingent upon the manufacturer’s commitment to
continual lot-testing programmes. Additionally, further
investigation into the failure modes that lead to inter-lot
variability and performance deterioration is needed, and
manufacturers should ideally be incentivized to investigate
lot anomalies.
6.4 Positive Control Wells
Finally, it is unclear how frequently quality assurance
services are taken advantage of at the community level, due
to the logistical and financial challenges associated with
shipping RDT samples to WHO testing centres and
receiving results back. An approach closer to the ideal
would be to provide for on-site testing of RDTs using
standardized positive control wells (PCWs) containing
lyophilized antigens. [126] PCWs for malaria RDTs have
been developed by FIND, but the products are still under‐
going validation, one of the key concerns with their
implementation being the potential for thermal degrada‐
tion in rural health care settings. An appropriate strategy
for addressing this issue might be to store positive controls
in centralized, temperature-controlled facilities and to
supply them intermittently to peripheral health clinics
during regular on-site supervisory visits. [125] If they are
made widely available by central regulatory agencies, the
use of positive control wells would likely serve to increase
confidence in test performance, and could play a key role
in reducing over-prescription of medication.
7. Economic Barriers
Rapid diagnostic tests have been advanced as the ideal
point-of-care diagnostic format, both for their simple and
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rapid operation, and for their affordability relative to
alternative methods of diagnosis. However, systematic
studies of their true economic benefit — both at the patient-
level and on the national scale — have thus far been limited
almost strictly to analysis of the roll-out of malaria RDTs,
starting in the early 2000s. Appropriate measures of the
cost-effectiveness of these malaria RDTs must take into
account not only their unit cost, but also more nuanced
values such as cost savings achieved from reduced over-
prescription of medications, reduced losses in patient
income due to more localized diagnostic options, and the
associated benefit to the broader national economy.
7.1 Cost-Effectiveness and Pricing
One study in Uganda found that at present, unsubsidized
unit costs for malaria RDTs tend to fall within the range of
US$2.54–2.83, which is much higher than the average value
of $0.53 that consumers are willing to pay. [127] In order to
ensure that RDTs are actually utilized at the community
level, this price gap must be covered by external subsidies,
most likely from the federal government. Studies show that
at an 85% subsidy level, the rate at which RDTs are used to
test febrile illnesses is doubled. [128] However, compliance
with negative RDT results is only partial, with 49% of study
participants over the age of five purchasing anti-malarial
medications regardless of the test’s outcome. This over-
medication in response to distrust of negative RDT results
drastically diminishes the cost-effectiveness of RDTs and
results in 10–250% higher incurred costs for RDTs than for
microscopic diagnosis, depending upon the local transmis‐
sion rates. [129] While this measure of cost-effectiveness
fails to account for the improved market penetration and
accessibility of the RDT format, it reinforces the point that
consistent compliance with test results is critical if RDTs are
to yield their maximal financial and health benefits.
While RDTs have been shown to be of financial benefit in
high disease transmission scenarios, in situations of lower
prevalence their cost-effectiveness is less clear-cut. Pro‐
grammes of mass screening and treatment (MSAT) based
on malaria RDTs have limited efficacy in reducing the
incidence of disease in low transmission settings, due to
large reservoirs of low-level asymptomatic cases in which
parasitaemia is below the limit of detection (LOD) of RDTs
— roughly 100 parasites/µl. Unless the LOD of RDTs can
be significantly improved, molecular methods such as
LAMP or nested PCR, which demonstrate LODs as low as
0.02 parasites/µl, will be of greater utility in elimination or
pre-elimination settings. [130] While RDTs will still be of
financial benefit in these low-transmission populations, it
will only be as a platform for confirmatory diagnosis of
acute infections.
8. Conclusions and Future Directions
Rapid diagnostic tests show great potential for meeting the
need for low-cost, rapid, point-of-care confirmatory tests
for symptomatic cases of infectious disease. Although at
present only malaria RDTs have achieved appreciable
market penetration and technological maturity, in coming
years the test format will be successfully adapted for the
diagnosis of a broad variety of vector-borne tropical
diseases, sexually transmitted infections and even non-
communicable conditions. The identification of a new
generation of biomarkers via the sensitive “omics” analysis
of complex patient samples will enable the sensitive and
specific diagnosis of these illnesses at the point-of-care,
reducing morbidity and mortality, and informing epide‐
miological models and elimination campaigns.
Throughout this process, the considerable infrastructure
and regulatory development that has occurred in the roll-
out of malaria RDTs will hopefully serve to jump-start
research, development, and validation of rapid diagnostic
tests for these new disease targets, as well as the creation of
efficient, high-coverage supply chains. By identifying the
myriad technical, biological, social, infrastructural, regula‐
tory, and economic issues that have contributed to the slow
market acceptance of RDTs thus far, and by proposing
context-appropriate solutions, it is hoped that the format
can be fundamentally improved, and that the same pitfalls
can be avoided for other disease contexts.
These fundamental paradigm shifts may already be
underway. In the near future, microfluidics-, paper- or
thread-based formats might supplant those based on
nitrocellulose membranes. [131–134] Devices based on
these novel modalities can be manufactured at scale using
existing infrastructure, and can be engineered to support
internal, multistep sample processing, allowing for facile
user operation. [135] Additionally, antibodies may soon be
replaced by thermostable, bio-orthogonal non-immuno‐
globulin affinity agents, reducing the cost of test produc‐
tion and increasing test stability in infrastructure-poor
contexts. [56, 136] RDTs may also be adapted for the
multiplexed detection of disparate pathogens, [87, 103]
allowing for the efficient diagnosis of patients with non-
specific clinical presentations. Finally, the spread of RDTs
may be supported by technologies leveraging the broad
availability of cell phones, for improved sensitivity and
reduced subjectivity in test line interpretation. [137]
Whatever the ultimate direction of development, the
progressive improvement of rapid diagnostic tests will
undoubtedly continue, driven by the format’s potential
applications in developed contexts (e.g., veterinary science,
environmental monitoring, biosecurity and triage
testing/in-home self-monitoring); by the rapidly expand‐
ing, government-subsidized market for low-cost diagnos‐
tics; and by the innate potential of RDTs to improve global
health by enabling point-of-care diagnosis of infectious
disease.
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